Do you want to read an article? Please log in or register.
Phase III randomized, double-blind study of paclitaxel with and without Everolimus in patients with advanced gastric or esophagogastric junction carcinoma who have progressed after therapy with a fluoropyrimidine/platinum-containing regimen (RADPAC)
Gastrointestinal Cancer